Drugs / MB09
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05338086 | Mar 2022 → Dec 2023 | postmenopausal osteoporosis | mAbxience Research S.L. | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MB09 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05338086 ↗ |
| Route | Subcutaneous | “administered as subcutaneous injection” NCT05338086 ↗ |